Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Interdiscip Sci ; 2024 Mar 14.
Article in English | MEDLINE | ID: mdl-38483753

ABSTRACT

Recognizing drug-target interactions (DTI) stands as a pivotal element in the expansive field of drug discovery. Traditional biological wet experiments, although valuable, are time-consuming and costly as methods. Recently, computational methods grounded in network learning have demonstrated great advantages by effective topological feature extraction and attracted extensive research attention. However, most existing network-based learning methods only consider the low-order binary correlation between individual drug and target, neglecting the potential higher-order correlation information derived from multiple drugs and targets. High-order information, as an essential component, exhibits complementarity with low-order information. Hence, the incorporation of higher-order associations between drugs and targets, while adequately integrating them with the existing lower-order information, could potentially yield substantial breakthroughs in predicting drug-target interactions. We propose a novel dual channels network-based learning model CHL-DTI that converges high-order information from hypergraphs and low-order information from ordinary graph for drug-target interaction prediction. The convergence of high-low order information in CHL-DTI is manifested in two key aspects. First, during the feature extraction stage, the model integrates both high-level semantic information and low-level topological information by combining hypergraphs and ordinary graph. Second, CHL-DTI fully fuse the innovative introduced drug-protein pairs (DPP) hypergraph network structure with ordinary topological network structure information. Extensive experimentation conducted on three public datasets showcases the superior performance of CHL-DTI in DTI prediction tasks when compared to SOTA methods. The source code of CHL-DTI is available at https://github.com/UPCLyy/CHL-DTI .

2.
Comput Struct Biotechnol J ; 23: 589-600, 2024 Dec.
Article in English | MEDLINE | ID: mdl-38274993

ABSTRACT

Single-cell RNA sequencing (scRNA-seq) is currently an important technology for identifying cell types and studying diseases at the genetic level. Identifying rare cell types is biologically important as one of the downstream data analyses of single-cell RNA sequencing. Although rare cell identification methods have been developed, most of these suffer from insufficient mining of intercellular similarities, low scalability, and being time-consuming. In this paper, we propose a single-cell similarity division algorithm (scSID) for identifying rare cells. It takes cell-to-cell similarity into consideration by analyzing both inter-cluster and intra-cluster similarities, and discovers rare cell types based on the similarity differences. We show that scSID outperforms other existing methods by benchmarking it on different experimental datasets. Application of scSID to multiple datasets, including 68K PBMC and intestine, highlights its exceptional scalability and remarkable ability to identify rare cell populations.

3.
Int J Mol Sci ; 24(9)2023 May 05.
Article in English | MEDLINE | ID: mdl-37176031

ABSTRACT

The accurate prediction of drug-target binding affinity (DTA) is an essential step in drug discovery and drug repositioning. Although deep learning methods have been widely adopted for DTA prediction, the complexity of extracting drug and target protein features hampers the accuracy of these predictions. In this study, we propose a novel model for DTA prediction named MSGNN-DTA, which leverages a fused multi-scale topological feature approach based on graph neural networks (GNNs). To address the challenge of accurately extracting drug and target protein features, we introduce a gated skip-connection mechanism during the feature learning process to fuse multi-scale topological features, resulting in information-rich representations of drugs and proteins. Our approach constructs drug atom graphs, motif graphs, and weighted protein graphs to fully extract topological information and provide a comprehensive understanding of underlying molecular interactions from multiple perspectives. Experimental results on two benchmark datasets demonstrate that MSGNN-DTA outperforms the state-of-the-art models in all evaluation metrics, showcasing the effectiveness of the proposed approach. Moreover, the study conducts a case study based on already FDA-approved drugs in the DrugBank dataset to highlight the potential of the MSGNN-DTA framework in identifying drug candidates for specific targets, which could accelerate the process of virtual screening and drug repositioning.


Subject(s)
Drug Discovery , Drug Repositioning , Benchmarking , Drug Delivery Systems , Neural Networks, Computer
4.
IEEE J Biomed Health Inform ; 27(10): 4639-4648, 2023 10.
Article in English | MEDLINE | ID: mdl-35759606

ABSTRACT

MicroRNAs (miRNAs) influence several biological processes involved in human disease. Biological experiments for verifying the association between miRNA and disease are always costly in terms of both money and time. Although numerous biological experiments have identified multi-types of associations between miRNAs and diseases, existing computational methods are unable to sufficiently mine the knowledge in these associations to predict unknown associations. In this study, we innovatively propose a heterogeneous graph attention network model based on meta-subgraphs (MSHGANMDA) to predict the potential miRNA-disease associations. Firstly, we define five types of meta-subgraph from the known miRNA-disease associations. Then, we use meta-subgraph attention and meta-subgraph semantic attention to extract features of miRNA-disease pairs within and between these five meta-subgraphs, respectively. Finally, we apply a fully-connected layer (FCL) to predict the scores of unknown miRNA-disease associations and cross-entropy loss to train our model end-to-end. To evaluate the effectiveness of MSHGANMDA, we apply five-fold cross-validation to calculate the mean values of evaluation metrics Accuracy, Precision, Recall, and F1-score as 0.8595, 0.8601, 0.8596, and 0.8595, respectively. Experiments show that our model, which primarily utilizes multi-types of miRNA-disease association data, gets the greatest ROC-AUC value of 0.934 when compared to other state-of-the-art approaches. Furthermore, through case studies, we further confirm the effectiveness of MSHGANMDA in predicting unknown diseases.


Subject(s)
MicroRNAs , Humans , MicroRNAs/genetics , Computational Biology/methods , Algorithms
5.
Cells ; 11(15)2022 08 08.
Article in English | MEDLINE | ID: mdl-35954300

ABSTRACT

Cancer is a highly heterogeneous disease, which leads to the fact that even the same cancer can be further classified into different subtypes according to its pathology. With the multi-omics data widely used in cancer subtypes identification, effective feature selection is essential for accurately identifying cancer subtypes. However, the feature selection in the existing cancer subtypes identification methods has the problem that the most helpful features cannot be selected from a biomolecular perspective, and the relationship between the selected features cannot be reflected. To solve this problem, we propose a method for feature selection to identify cancer subtypes based on the heterogeneity score of a single gene: HSSG. In the proposed method, the sample-similarity network of a single gene is constructed, and pseudo-F statistics calculates the heterogeneity score for cancer subtypes identification of each gene. Finally, we construct gene-gene networks using genes with higher heterogeneity scores and mine essential genes from the networks. From the seven TCGA data sets for three experiments, including cancer subtypes identification in single-omics data, the performance in feature selection of multi-omics data, and the effectiveness and stability of the selected features, HSSG achieves good performance in all. This indicates that HSSG can effectively select features for subtypes identification.


Subject(s)
Neoplasms , Gene Regulatory Networks , Humans , Neoplasms/genetics
6.
Cells ; 11(9)2022 04 22.
Article in English | MEDLINE | ID: mdl-35563727

ABSTRACT

Cancer prognosis is an essential goal for early diagnosis, biomarker selection, and medical therapy. In the past decade, deep learning has successfully solved a variety of biomedical problems. However, due to the high dimensional limitation of human cancer transcriptome data and the small number of training samples, there is still no mature deep learning-based survival analysis model that can completely solve problems in the training process like overfitting and accurate prognosis. Given these problems, we introduced a novel framework called SAVAE-Cox for survival analysis of high-dimensional transcriptome data. This model adopts a novel attention mechanism and takes full advantage of the adversarial transfer learning strategy. We trained the model on 16 types of TCGA cancer RNA-seq data sets. Experiments show that our module outperformed state-of-the-art survival analysis models such as the Cox proportional hazard model (Cox-ph), Cox-lasso, Cox-ridge, Cox-nnet, and VAECox on the concordance index. In addition, we carry out some feature analysis experiments. Based on the experimental results, we concluded that our model is helpful for revealing cancer-related genes and biological functions.


Subject(s)
Genomics , Neoplasms , Genome , Genomics/methods , Humans , Neoplasms/genetics , Proportional Hazards Models , Survival Analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...